Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Allergy Therapeutics plc
DescriptionUltra-short course allergen-specific immunotherapy comprising modified allergens, microcrystalline tyrosine (MCT) and monophosphoryl lipid A (MPL)
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationAllergy
Indication DetailsPrevent seasonal grass allergy
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today